Amylyx Pharmaceuticals Q1 net loss widens more than expected on higher R&D costs

Amylyx Pharmaceuticals

07/05/2026 12:22

Overview

U.S. biotech firm's Q1 net loss widened, missing analyst expectations

Q1 adjusted EPS missed analyst consensus

Higher R&D costs driven by avexitide clinical development increased quarterly expenses

Outlook

Topline data from Phase 3 LUCIDITY trial of avexitide expected in Q3 2026

Company anticipates potential commercial launch of avexitide in 2027 if approved

Amylyx expects cash runway to fund operations into 2028

Result Drivers

AVEXITIDE DEVELOPMENT COSTS - Higher R&D expenses were mainly due to increased spending on avexitide clinical development for PBH

MILESTONE PAYMENTS - $4 mln in milestone payments to Gubra recognized after selection of AMX0318 as a development candidate

CONSULTING AND PROFESSIONAL SERVICES - SG&A expenses rose mainly due to increased consulting and professional services

Company press release: ID:nBw81q3D5a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
Miss
-$0.37
-$0.33 (8 Analysts)
Q1 Net Income
Miss
-$41.28 mln
-$37.44 mln (8 Analysts)
Q1 Operating Income
Miss
-$43.78 mln
-$41.64 mln (9 Analysts)
Q1 Cash & Investments
$279.8 mln
Q1 Operating Expenses
$43.78 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Amylyx Pharmaceuticals Inc is $21.50, about 33.9% above its May 6 closing price of $16.06

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)